Third Wave Rises 8.4 Percent | GenomeWeb
Shares of Third Wave Technologies rose 8.4 percent for the five-day trading period ended Tuesday. The firm’s stock is up 17.7 percent since announcing on Dec. 5 that it had received the CE Mark for its HPV molecular diagnostic test, allowing it to sell the test throughout the European Union.
 
Qiagen led decliners for the week with a drop of 5.9 percent. Overall, 16 of the 21 stocks in the BCW Index lost value during the tracking period, and the Index closed down 1.1 percent.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.